Neville Rodie & Shaw Decreased By $462,130 Its Lam Research (LRCX) Position; Shorts at Agios Pharmaceuticals (AGIO) Lowered By 9.79%

February 21, 2018 - By Peter Erickson

Agios Pharmaceuticals Inc (NASDAQ:AGIO) had a decrease of 9.79% in short interest. AGIO’s SI was 6.07 million shares in February as released by FINRA. Its down 9.79% from 6.72 million shares previously. With 1.21M avg volume, 5 days are for Agios Pharmaceuticals Inc (NASDAQ:AGIO)’s short sellers to cover AGIO’s short positions. The SI to Agios Pharmaceuticals Inc’s float is 14.12%. The stock decreased 0.22% or $0.17 during the last trading session, reaching $77.53. About 405,575 shares traded. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has risen 8.52% since February 21, 2017 and is uptrending. It has underperformed by 8.18% the S&P500.

Neville Rodie & Shaw Inc decreased Lam Research Corp (LRCX) stake by 5.13% reported in 2017Q3 SEC filing. Neville Rodie & Shaw Inc sold 2,498 shares as Lam Research Corp (LRCX)’s stock rose 32.64%. The Neville Rodie & Shaw Inc holds 46,160 shares with $8.54M value, down from 48,658 last quarter. Lam Research Corp now has $31.52 billion valuation. The stock increased 2.94% or $5.53 during the last trading session, reaching $193.44. About 3.30M shares traded. Lam Research Corporation (NASDAQ:LRCX) has risen 107.86% since February 21, 2017 and is uptrending. It has outperformed by 91.16% the S&P500.




Among 16 analysts covering Agios Pharmaceuticals (NASDAQ:AGIO), 12 have Buy rating, 0 Sell and 4 Hold. Therefore 75% are positive. Agios Pharmaceuticals had 44 analyst reports since July 23, 2015 according to SRatingsIntel. The company was maintained on Wednesday, November 1 by RBC Capital Markets. The stock of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) earned “Outperform” rating by Northland Capital on Thursday, July 23. As per Wednesday, August 5, the company rating was maintained by Roth Capital. The stock of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) earned “Neutral” rating by Janney Capital on Monday, June 26. Oppenheimer maintained the stock with “Buy” rating in Monday, June 26 report. The rating was upgraded by JP Morgan on Monday, June 13 to “Overweight”. The firm earned “Outperform” rating on Wednesday, August 2 by Leerink Swann. The stock of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) earned “Overweight” rating by JP Morgan on Thursday, February 15. The firm earned “Buy” rating on Thursday, February 15 by Credit Suisse. The firm earned “Buy” rating on Monday, October 24 by Needham.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. The company has market cap of $4.45 billion. It is developing Enasidenib, a potent inhibitor of the mutated isocitrate dehydrogenase 2 protein that is in Phase 1/2 clinical trial for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase 3 clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination trial for patients with newly diagnosed AML. It currently has negative earnings. The firm is also developing Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase 1 clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase 1 clinical trial for advanced solid tumors; Phase 3 clinical trial for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination and Phase 3 clinical trials for newly diagnosed AML patients.

Since August 22, 2017, it had 0 buys, and 22 sales for $24.95 million activity. On Friday, September 1 Schenkein David P sold $373,200 worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) or 6,000 shares. Biller Scott also sold $195,000 worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) on Wednesday, January 10. Another trade for 4,000 shares valued at $284,380 was sold by Cantley Lewis Clayton Jr.. Bowden Christopher had sold 2,000 shares worth $155,305. Hoerter Steven L. sold 25,000 shares worth $1.87 million. 2,150 shares were sold by Alenson Carman, worth $161,250.

Investors sentiment decreased to 1.21 in Q3 2017. Its down 0.83, from 2.04 in 2017Q2. It dropped, as 22 investors sold Agios Pharmaceuticals, Inc. shares while 44 reduced holdings. 29 funds opened positions while 51 raised stakes. 44.69 million shares or 0.07% less from 44.72 million shares in 2017Q2 were reported. 16 are owned by Tarbox Family Office Inc. Parametric Port Associate Ltd reported 21,565 shares. State Bank Of Mellon Corporation accumulated 176,405 shares or 0% of the stock. Tiaa Cref Inv Management Limited Liability Corp invested in 112,813 shares. Guggenheim Lc owns 61,676 shares or 0.01% of their US portfolio. Goldman Sachs Group, a New York-based fund reported 932,156 shares. Marshall Wace Llp has invested 0.03% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Verition Fund Mgmt has invested 0.04% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Mutual Of America Capital Management Ltd Co has invested 0.03% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Parallax Volatility Advisers Lp owns 0% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) for 30,734 shares. Geode Mgmt Ltd Co holds 365,439 shares or 0.01% of its portfolio. Clearbridge Invs Ltd Liability Company, a New York-based fund reported 1.53M shares. Bancorp Of Montreal Can holds 0% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) or 2,031 shares. Alliancebernstein L P invested in 33,792 shares or 0% of the stock. Teachers Retirement System Of The State Of Kentucky reported 0.04% of its portfolio in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO).

Investors sentiment increased to 1.02 in Q3 2017. Its up 0.04, from 0.98 in 2017Q2. It improved, as 51 investors sold LRCX shares while 238 reduced holdings. 87 funds opened positions while 207 raised stakes. 146.35 million shares or 1.92% less from 149.22 million shares in 2017Q2 were reported. Nj State Employees Deferred Compensation Plan reported 15,625 shares. Nippon Life Insur reported 12,217 shares. Eaton Vance Management stated it has 0.02% in Lam Research Corporation (NASDAQ:LRCX). Hanseatic Management Incorporated holds 1,933 shares or 0.41% of its portfolio. Columbus Circle Investors holds 1.01% or 319,011 shares. Westwood Incorporated reported 280,633 shares stake. Oppenheimer Asset Mngmt, New York-based fund reported 741 shares. 247 are held by Alpha Windward Ltd Liability. Pathstone Family Office Limited Liability Corp holds 200 shares. Natl Pension Service has invested 0.17% in Lam Research Corporation (NASDAQ:LRCX). Jpmorgan Chase holds 0.13% of its portfolio in Lam Research Corporation (NASDAQ:LRCX) for 3.31M shares. Utah Retirement Sys holds 0.12% in Lam Research Corporation (NASDAQ:LRCX) or 29,579 shares. Baldwin Inv Ltd Liability Corp owns 9,175 shares for 0.64% of their portfolio. Grassi Management invested in 0.23% or 7,375 shares. 227,000 were accumulated by Eventide Asset Mgmt Limited.

Analysts await Lam Research Corporation (NASDAQ:LRCX) to report earnings on April, 17. They expect $4.36 earnings per share, up 55.71% or $1.56 from last year’s $2.8 per share. LRCX’s profit will be $710.46M for 11.09 P/E if the $4.36 EPS becomes a reality. After $4.34 actual earnings per share reported by Lam Research Corporation for the previous quarter, Wall Street now forecasts 0.46% EPS growth.

Since September 11, 2017, it had 0 buys, and 11 sales for $12.77 million activity. ARCHER TIMOTHY sold 8,691 shares worth $1.49 million. Another trade for 750 shares valued at $131,250 was made by NEWBERRY STEPHEN G on Monday, September 18. Varadarajan Seshasayee had sold 25,453 shares worth $5.47M.

Among 25 analysts covering Lam Research Corporation (NASDAQ:LRCX), 24 have Buy rating, 0 Sell and 1 Hold. Therefore 96% are positive. Lam Research Corporation has $270 highest and $52 lowest target. $229.14’s average target is 18.46% above currents $193.44 stock price. Lam Research Corporation had 79 analyst reports since September 17, 2015 according to SRatingsIntel. The firm has “Underperform” rating by RBC Capital Markets given on Monday, October 5. The stock has “Underperform” rating by RBC Capital Markets on Thursday, October 22. The rating was maintained by DA Davidson on Thursday, October 6 with “Buy”. Morgan Stanley maintained it with “Buy” rating and $16800 target in Friday, July 7 report. The stock of Lam Research Corporation (NASDAQ:LRCX) has “Outperform” rating given on Wednesday, October 21 by Cowen & Co. The stock has “Buy” rating by Citigroup on Friday, August 12. Morgan Stanley initiated the stock with “Overweight” rating in Tuesday, December 15 report. As per Friday, October 9, the company rating was maintained by Needham. Credit Suisse maintained the stock with “Buy” rating in Wednesday, October 18 report. Citigroup maintained Lam Research Corporation (NASDAQ:LRCX) rating on Thursday, October 6. Citigroup has “Buy” rating and $108 target.

Neville Rodie & Shaw Inc increased Fedex Corp (NYSE:FDX) stake by 1,477 shares to 29,072 valued at $6.56M in 2017Q3. It also upped Rio Tinto Plc Adr Sponsored (NYSE:RIO) stake by 13,500 shares and now owns 47,100 shares. Chubb Limited Com was raised too.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.